Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $32 at Mizuho

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $32 at Mizuho

Goldman Sachs Downgrades Amylyx Pharmaceuticals inc. (AMLX) to Neutral

March 8, 2024 2:35 PM EST

Goldman Sachs analyst Corinne Jenkins downgraded Amylyx Pharmaceuticals inc. (NASDAQ: AMLX) from Buy to Neutral with a price target of $4.00 (from $40.00).

The analyst comments "This morning, AMLX reported that the Ph3 PHOENIX trial evaluating the use of Relyvrio in patients with amyotrophic lateral sclerosis (ALS) did not meet its primary or secondary endpoints... More